-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3949 Low-Dose Corticosteroids and Eltrombopag in the Treatment of Newly Diagnosed Adult Immune Thrombocytopenia: A Multicenter, Phase 2 Clinical Trial

Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical trials, Bleeding and Clotting, Combination therapy, Adult, Clinical Practice (Health Services and Quality), Clinical Research, Diseases, Thrombocytopenias, Treatment Considerations, Study Population, Human
Monday, December 9, 2024, 6:00 PM-8:00 PM

Qi Liu1*, Yingying Shen1*, Lihong Shou2*, Yongming Xia3*, Sai Chen4*, Mei Zhou5*, Xiaohua Xu6*, Liqiang Wu1*, Jian-Zhi Zhao7*, Xiaohui Dong8*, Linglong Xu4*, Chunmeng Rong3*, Di Qiu5*, Wenbin Liu1*, Huijin Hu1*, Yuechao Zhao1*, Yun Zhang1*, Linjie Li9*, Yaping Xie, MD10*, Xiaojun Xu, MD11*, Huifang Jiang12*, Hui Zeng13*, Jiaping Fu14*, Li Huang15*, Xia Lin16*, Dan Chen17*, Yuhong Zhou1*, Baodong Ye18*, Yiping Shen1* and Dijiong Wu, MD, PhD1

1Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
2Department of Hematology, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, China
3Department of Hematology, Yuyao People's Hospital of Zhejiang Province, Yuyao, Zhejiang Province, China
4Department of Hematology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang Province, China
5Department of Hematology, Zhuji People's Hospital, Zhuji, Zhejiang Province, China
6Department of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
7Shaoxing Central Hospital, Shaoxing, CHN
8Department of Hematology, Huzhou Central Hospital, Huzhou, Zhejiang Province, China
9Lishui Municipal Central Hospital, Lishui, CHN
10Department of Hematology, Affiliated Hangzhou First People's Hospital, Hangzhou, Zhejiang, CHN
11Children’s Hospital of Zhejiang University School of Medicine, Hangzhou, China
12Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, China
13Department of Hematology, the First Affiliated Hospital of Jiaxing University, Jiaxing, China
14Department of Hematology, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University), Shaoxing, Zhejiang Province, China
15Department of Hematology, Jinhua People's Hospital, Jinhua, Zhejiang Province, China
16Department of Hematology, The First People's Hospital of Huzhou, Huzhou, Zhejiang Province, China
17The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, CHN
18The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by decreased platelet (PLT) count in peripheral blood and bone marrow megakaryocyte dysfunction. The standard first-line treatment of newly diagnosed ITP was still corticosteroids (CIS), intravenous immunoglobulin (IVIG) or anti-D IG for those PLT≤30×109/L. According to the present international consensus or clinical guidelines, the timeline for cease or starting maintenance treatment (no more than 5mg daily) of CIS should within 6-8 weeks. However, many relapses happened practically, and need to switch into second line treatment such as thrombopoietin receptor agonist (TPO-RA). Eltrombopag (EPAG), the first oral non-peptide TPO-RA, achieved ~80% response in chronic ITP patients. The initial recommend dose of EPAG was 25mg according to Chinese Guideline, and the response rate increased if the daily dose increased to 50mg or 75mg (22.22%, 45.45 % and 65.52%, respectively), however the financial burden increased accordingly, especially for patients in developing country. It is of great clinical significance if we can invoke a treatment protocol that could gain all the benefits, including quick response, timely CIS withdrawal as well as high sustained response. Herein, we raise a multicenter phase 2 clinical trial, which aimed to explore the efficacy of low-dose corticosteroids (LD-CIS) plus low-dose eltrombopag (LD-EPAG) for newly diagnosed, treatment-naïve ITP patients.

The study included three phases: 1) core treatment period (8 weeks), patients received fixed LD-CIS (weight≤ 50kg, 20 mg/d; weight> 50kg, 0.4 mg/kg/d) for 3 weeks and reduced gradually to target dosage within 8 weeks, with fixed LD-EPAG (25 mg daily) treatment; 2) decrement and discontinuation period (12 weeks): EPAG gradually tapered if the PLT count maintain above 100×109/L over 2/3 of the core treatment period; 3) follow-up period (6 months): LD-CIS and LD-EPAG ceased and observe the sustained response for 6 months. The primary endpoint was the ratio of CIS discontinuation or maintenance dose less than 5mg QD within 8 weeks with a PLT≥ 50×109/L. The secondary endpoint of study was durable response after EPAG discontinuation or maintenance dose ≤ 25mg BIW. Between July 2022 and March 2024, 16 centers participate in, and 41 patients from 5 centers were screened for eligibility. Sixteen cases were excluded, and 23 patients were ultimately enrolled and finished the whole study. 23 patients were ultimately enrolled and finished the whole study. The median age was 53.83 (range 23-88) years old. For efficacy assessment, all the patients achieved an increased PLT from baseline. The complete response (CR, PLT ≥ 100×109/L) was achieved in 60.87% (14/23) patients at the end of 2nd week observation, which increased to 84.21% (16/19) at the end of 12th weeks. As noted, the overall response rate (ORR) reached 100% in 2nd weeks and maintained above 90% throughout the study. The median intervals time required for platelet to reach 30×109/L and 100×109/L for the first time were 6 (2-18) and 14.5 (4-45) days, respectively.

Out of 23 patients received our treatment protocol, 22 (95.65%) patients achieved the primary endpoint, except for one patient exhibited CIS-dependent. The secondary endpoint of study was the proportion of patients who achieved EPAG discontinuation or maintenance dose ≤ 25mg BIW until Week 20, which was 52.94% in 9 out of evaluable 17 patients, of which, 8 cases accomplished SRoT with a median durable response of 5.5 (range 2.75-5) months. In addition, the median bleeding score pretreatment was 2 (0-4), which was decreased at each point post-treatment by paired t-test. Clinical assessment of ITP commonly focusses on platelet counts and risk of bleeding, fatigue and HRQoL were also longitudinally evaluated in our cohort. The results showed that there were no significant differences in fatigue score after the combination therapy, while mental health (MH) score was improved. In addition, no severe adverse events were observed during the whole study, the treatment related side effect such as impaired glucose tolerance, liver dysfunction, etc.

In summary, the combination of low-dose corticosteroids and eltrombopag can exert a quick and durable response in newly diagnosed ITP, and partly improve their quality of life. This regimen represents a potential first-line treatment, but further randomized controlled studies are needed to consolidate this conclusion.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH